Aderholt is disappointed that the U.S. Supreme Court ruled to uphold full access to the abortion pill

Pro-Life groups suffered a serious setback on Wednesday when the U.S. Supreme Court announced that it has upheld a Biden Administration rule allowing full access to the controversial abortion pill – mifepristone. Congressman Robert Aderholt (R-Haleyville) released a statement expressing his disappointment with the ruling.

"I am disappointed to learn that the Supreme Court upheld full access to the dangerous abortion pill, mifepristone," said Rep. Aderholt in a statement. "While I fully respect the Court, this decision will have a profoundly negative impact on the safety of women across the United States."

"From the moment the Food and Drug Administration fast-tracked the approval of this drug, then decided to loosen restrictions on mifepristone in 2016 and 2021, their stance has been clear: the FDA is willing to compromise the safety of women to ally with a Democrat political agenda and score political points," continued Aderholt. "The American people deserve to know exactly what this ruling means: this pill continues to be prescribed further into a pregnancy beyond the approved limits, without adequate medical supervision, resulting in increasing numbers of women requiring emergency care. The FDA's own label says 1 in 25 women who take the drug will end up in emergency care."

Rep. Aderholt expressed deep concerns about the safety of the abortion drug.

"The dangerous drug will also continue to be widely available by mail, eliminating the requirement for medical supervision and undermining state pro-life laws," said Aderholt. "The Food and Drug Administration has a stated mission of protecting public health and ensuring the safety and security of human drugs, and they are violating the public trust with these irresponsible decisions: they must quickly reverse course on loosening these restrictions.

Aderholt lamented that this ruling will ultimately lead to tremendous medical complications for women.

"This Supreme Court decision will unfortunately allow policies to continue which endanger the health and safety of women," said Aderholt. "I call on the Food and Drug Administration to change their current course and prioritize the safety of women by placing strong parameters on the dangerous drug, mifepristone. Until then, I remain committed to working diligently with my colleagues in Congress to protect life and protect women."

The Court ruled unanimously that a group of anti-abortion doctors lacks legal standing to challenge access to mifepristone. The drug is one of the two most common drugs used in medically terminate a pregnancy.

The opinion was written by Justice Brett Kavanaugh. The Court sided with the Biden administration and Danco who manufactures the name brand version of mifepristone. The Court reversed a lower court decision that would have made it more difficult to obtain the drug, which is used in about two-thirds of U.S. abortions.

The drug will remain widely available to people up to the 10th week of pregnancy and can be purchased from most pharmacies and even through the mail.

The decision is a victory for the Biden administration and the FDA.

Rep. Aderholt is the Chairman of the House Values Action Team (VAT), and the Appropriations Subcommittee on Labor, Health and Human Services, and Education.

To connect with the author of this story, or to comment, email brandonmreporter@gmail.com